logo
    Comparative performance of cardiovascular risk prediction models in people living with HIV
    1
    Citation
    38
    Reference
    10
    Related Paper
    Citation Trend
    Abstract:
    Current cardiovascular risk assessment in people living with HIV is based on general risk assessment tools; however, whether these tools can be applied in sub-Saharan African populations has been questioned.The study aimed to assess cardiovascular risk classification of common cardiovascular disease (CVD) risk prediction models compared to the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) 2010 and 2016 models in people living with HIV.Cardiovascular disease risk was estimated by Framingham Cardiovascular and Heart Disease (FHS-CVD, FHS-CHD), Atherosclerotic Cardiovascular Disease (ASCVD) and D:A:D 2010 and 2016 risk prediction models for HIV-infected participants of the Ndlovu Cohort Study, Limpopo, rural South Africa. Participants were classified to be at low (< 10%), moderate (10% - 20%), or high-risk (> 20%) of CVD within 10 years for general CVD and five years for D:A:D models. Kappa statistics were used to determine agreement between CVD risk prediction models. Subgroup analysis was performed according to age.The analysis comprised 735 HIV-infected individuals, predominantly women (56.7%), average age 43.9 (8.8) years. The median predicted CVD risk for D:A:D 2010 and FHS-CVD was 4% and for ASCVD and FHS-CHD models, 3%. For the D:A:D 2016 risk prediction model, the figure was 5%. High 10-year CVD risk was predicted for 2.9%, 0.5%, 0.7%, 3.1% and 6.6% of the study participants by FHS-CVD, FHS-CHD, ASCVD, and D:A:D 2010 and 2016. Kappa statistics ranged from 0.34 for ASCVD to 0.60 for FHS-CVD as compared to the D:A:D 2010 risk prediction model.Overall, predicted CVD risk is low in this population. Compared to D:A:D 2010, CVD risk estimated by the FHS-CVD model showed similar overall results for risk classification. With the exception of the D:A:D model, all other risk prediction models classified fewer people to be at high estimated CVD risk. Prospective studies are needed to develop and validate CVD risk algorithms in people living with HIV in sub-Saharan Africa.
    Seperti pada dewasa, teknik regional anestesi pada pediatrik kini makin popular digunakan oleh ahli anestesikarena keuntungannya. Namun demikian selalu ada risiko dan kemungkinan timbulnya komplikasi dari setiap tindakan yang dilakukan, termasuk tindakan anestesi regional pada pediatrik. Insidensi komplikasi anestesi regional pada pediatrik tidak banyak, dan kalaupun terjadi komplikasi adalah minor. Komplikasi bisa diakibatkan dari identifikasi ruang saraf, alat, obat, teknis tindakan anestesi regionalnya dan komplikasi lainnya.Walaupun tidak banyak kejadian komplikasi regional anestesi yang dilaporkan pada pediatrik, dan bukanlah komplikasi yang fatal, teknik regional anestesi pada pediatrik harus dilakukan dengan lebih hatihati, pertimbangan risiko dan keuntungannya untuk menghindari terjadinya komplikasi, terlebih karena kebanyakan komplikasi dapat dihindari dengan mempelajari teknik yang benar, menggunakan peralatan yang sesuai, dan sangat menerapkan prinsip keamanan pada pasien dengan baik.
    Citations (0)
    Genentech is partnering with the German cancer company Affimed to develop immunotherapies for multiple kinds of solid and blood cancers. Affimed is developing therapies that engage natural killer cells of the innate immune system to help direct them to attack cancer cells. Genentech will pay Affimed $96 million up front and up to $5 billion more in potential payments.
    The nationally-recognized Susquehanna Chorale will delight audiences of all ages with a diverse mix of classic and contemporary pieces. The ChoraleAƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚¢AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚€AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚™s performances have been described as AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚¢AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚€AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚œemotionally unfiltered, honest music making, successful in their aim to make the audience feel, to be moved, to be part of the performance - and all this while working at an extremely high musical level.AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚¢AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚€AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚ƒAƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚ƒAƒÂƒA‚‚AƒÂ‚A‚‚AƒÂƒA‚ƒAƒÂ‚A‚‚AƒÂƒA‚‚AƒÂ‚A‚ Experience choral singing that will take you to new heights!
    Citations (0)